Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
Fulcrum Therapeutics (NASDAQ: FULC) announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fulcrum Therapeutics (NASDAQ: FULC) announced its participation in two upcoming investor conferences. The first is the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 2:35 p.m. PT, featuring a fireside chat. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 4:30 p.m. ET, also including a fireside chat. Interested investors can listen to live webcasts through the Investor Relations section of Fulcrum's website, with archived replays available for 30 days.
Details
News Market Reaction – FULC
The recorded move for FULC in the trading session of this news was -4.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:
- Credit Suisse 31st Annual Healthcare Conference
Tuesday, November 8, 2022 at 2:35 p.m. PT (Fireside Chat)
- Piper Sandler 34th Annual Healthcare Conference
Tuesday, November 29, 2022 at 4:30 p.m. ET (Fireside Chat)
Live audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter @FulcrumTx and LinkedIn.
Contacts:
Investors
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200
Media
Dee Smith
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
dsmith@fulcrumtx.com
202-746-1324
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.